The aim of the study was to determine the most effective medical treatment of patients with chronic pancreatitis, by using either pancreatin alone or in combination with proton pump inhibitor (PPI) 
INTRODUCTION
Chronic pancreatitis (CP) is a chronic and permanently progressive non-infectious pancreas inflammation, which is accompanied by destruction and fibrosis of its parenchyma. Even though many etiological factors of CP, such as alcohol consumption, smoking, ductus pancreaticus obstruction, genetic factors and others, are known, pathophysiological mechanisms of the disease are always intrapancreatic activation of digestive enzymes, inflammation and exocrine insufficiency. Recurrent or persistent abdominal pain, as well as exocrine and endocrine insufficiency, are characteristic to CP.
Treatment of CP involves a range of various approachesmedical, endoscopic therapy, surgery, etc. Medical therapy is the main method of CP treatment. In recent years a range of various treatment methods were proposed -use of pancreas enzyme preparations, analgesics, analogues of somatostatin, antidepressants, antioxidants and others. Although the applied preparation spectrum is wide, the outcomes of treatments are often unsatisfactory. The results of clinical studies are contradictory (Brown et al., 1997) . The various national illness treatment guidelines recommend a symptomatic medical therapy. In addition, preparation groups are selected step by step depending on the effect achieved (Warshaw et al., 1998; de-Madaria et al., 2013) . Presently, widely approved tactics of medical treatment of CP are not yet developed and discussion of effective therapy persists.
Pancreas injury progression in case of CP is related to various factors -activation of digestive enzymes in the pancreas (Salija et al., 1999) , activation of inflammatory cells (Grady et al., 1997) , reactive oxygen species, COX-2 production (Song et al., 2002) and others. 95% of CP patients suffer from abdominal pain, the cause of which in case of CP is increase of pressure in parenchymatous tissue of pancreas and its ducts; inflammation; compression of surrounding nerves; ischemia of tissues and infiltration of the organ's nerves with immune cells (Slaff et al., 1984; di Mola et al., 2008) .
Presently, one of the most popular CP medical treatment methods is oral use of pancreas enzymes, which affect cholecystokinin (CCK) only, reduce pancreas activity, provide analgesic effect and substitute exocrine function. The described method does not reduce secretine effects -production of pancreas bicarbonates and water. In theory, reduction of secretine effects can be achieved by inhibition of ATF-ases, which are linked to proton pumps in pancreas duct cells. A recent study confirmed the existence of proton pumps in pancreas duct cells of rats (Novak et al., 2011) . The study successfully showed the ability of omeprazole to reduce secretine induced pancreas duct cell secretion by up to 86%. The non-steroidal anti-inflammatory drug (NSAID) in case of CP is usually used to reduce abdominal pain (Warshaw et al., 1998; Frulloni et al., 2010; de-Madaria et al., 2013) .
The authors of the present study elaborated a protocol for medical treatment of CP, named PNP therapy. This therapy utilises a combination of pancreatin, NSAID and proton pump inhibitor (PPI) (Fig. 1) . Pancreatin is an animal pancreas extract preparation, the use of which is aimed at reduction of CCK secretion and, consequently, at reduction of secretion of trypsinogen and other pancreas enzymes, as well as supplementation of the deficient pancreas digestive enzymes into duodenum. According to the literature, pancreatin has an analgesic effect (Isaksson and Ihse, 1983; Slaff et al., 1984) . NSAID provides analgesic and anti-inflammatory effects. The aim of PPI is to block the secretion of gastric HCl, increase the level of pH in stomach and duodenum, as well as reduce gastric and duodenum content volume. An increased level of pH in duodenum causes CCK and reduction of pancreas enzyme secretion and reduction of pancreas parenchyma autolysis. Due to a reduced duodenum volume content and increased pH, secretine production is also decreased, which, in turn, causes a decline of bicarbonate and water production in pancreas ducts. As a result of these processes, pressure in pancreas ducts and tissue autolysis are reduced, which leads to reduction of abdominal pain. PPI also protects the pancreatin from inactivation due to HCl effects and protects gastrointestinal mucosa from possible NSAID-induced damage.
Evidence suggests that when effects occur on the three main pathogenetic mechanisms of CP -increased pancreas activity, inflammation and exocrine insufficiency -it is possible to achieve a better CP clinical treatment effect. The purpose of the given study is to determine the most effective medical therapy of CP among pancreatin monotherapy, pancreatin and PPI combined therapy, as well as combined pancreatin, PPI and NSAID therapy.
MATERALS AND METHODS
The study was conducted in the Centre (Anonymous, 2001) and WMA Declaration of Helsinki (Anonymous, 1964) . One hundred and six patients with confirmed diagnosis of CP according to MANNHEIM criteria (Schneider et al., 2007) were investigated in the prospective controlled randomised study. The patients involved did not require surgical or endoscopic treatment. The age of patients, of both sexes, was between 20 and 76 years. Exclusion criteria were as follows: malignant diseases, stomach and duodenum ulcer, severe liver and kidney diseases, acute cerebral and myocardial infarction, significant heart failure, as well as mental diseases. Before and after onemonth medical treatment, all patients had their body mass index (BMI) assessed. Clinical blood analysis was also conducted: blood hemoglobin, RBC (red blood cells) and WBC (white blood cells) count, erythrocyte sedimentation rate (ESR) (standard methods). Blood biochemical analysis included glucose, ASAT, ALAT, a-amylase, urea (standard methods). Other completed tests were fecal microscopy (steatorrhea, Drummey et al., 1961) , benzidine (fecal occult blood), and fecal elastase-1 (ELISA polyclonal antibody method). In addition, abdominal ultrasonoscopy and assessment of quality of life according to EORTC QLQ-C30 and QLQ-PAN26 questionnaires were carried out. Before treatment all patients had fibrogastroscopy. During treatment, patients made daily notes of abdominal pain, bowel movements and appetite loss, based on specially designed criteria. To assess abdominal pain, a standard 10 cm visual analogue scale (VAS) was used. Modified results were used in analysis, which were classified as mild, moderate and severe pain. Criteria for abdominal pain, bowel movements and appetite loss assessment are given in Table 1 . Summed counts of the above symptoms were determined for the first and the last five days of treatment. The clinical course severity of CP was assessed using a quantitative indicator -clinical pancreatic index (CPI). CPI is based on CP progression criteria. CPI involves assessment and summarisation of CP severity indicators such as number of CP related surgical operations in anamnesis, number of hospitalisations due to CP, weight loss, abdominal pain and steatorrhea severity, daily bowel movements, other dyspeptic complaints, and glucose intolerance. A higher CPI is associated with a more severe clinical course CP. The maximum CPI score is 25. Depending on the score, severity of CP clinical course is assessed as follows: mild -6-8 points, moderate -9-15, severe -16-25 points (Table 2) .
For assessment of quantitative pancreas structural changes, a visual pancreatic index (VPI) was used (Orïikovs et al., 2007) . VPI is based on six pancreas visual parameter groups: pancreas head size, pancreas echostructure, calcinates, ductus pancreaticus diameter, pseudocysts, and other. Every pancreas visual parameter was classified depending on its severity, using a 0 to 3 point system. The total VPI is estimated as the sum of all parameter points. Changes in CP were classified depending on severity -total score: 0-3 points -CP diagnosis is doubtful; 4-8 pointsmild changes; 9-14 points -moderate changes; 15-21 -severe changes (see Table 3 ). Abdominal ultrasonography data were used for calculation of VPI; however, for VPI calculation other sources can be used, such as endoscopic ultrasonography, abdominal computed tomography, and endoscopic retrograde cholangeopancreatography.
The patients were divided in three groups, depending on type of therapy. Division of patients and types of therapy are described in Table 4 . The medical treatment extended for one month.
Pangrol 25 000 consists of enteric coated microspheres of pancreatin. One Pangrol 25 000 capsule lipase activity corresponds to 25 000 EPU (European Pharmacopoeia units), amylase activity not less than 22 500 EPU and protease activity not less than 1250 EPU. The manufacturer of Pangrol 25 000 is Berlin-Chemie AG (Menarini Group). Every Omeprazols capsule contains 20 mg of omeprazole in a hard gelatine capsule. Omeprazols produced by Olainfarm JSC was used in the research. Airtal is a coated tablet that con- Number of surgical procedures due to CP complications in anamnesis no -0; one -1; two -2; three and more -3
Efficiency of outpatient treatment effective -0; ineffective-2 Number of hospitalizations due to CP in anamnesis no -0; one-1; two-2; three and more -3
Loss of weight (kg) 0 kg -0; less than 3 kg -1; 3 -5 kg -2, 5 kg -3
Severity of pain VAS no pain -0, mild -1; moderate -2; severe-3
Degree of steatorrhea 0 or + -0; ++ -1; +++ -2; ++++ and more -3
Number of daily defecations no -0; one-1; two -2; three and more -3
Other dyspeptic complaints (abdominal bloating, borborygmus, nausea, postprandial abdominal discomfort) no -0; one -1; two -2; three and more -3
Glucose tolerance Normal -0, impaired -1, diabetes mellitus -2 CP, chronic pancreatitis; VAS, visual analogue scale tains 100 mg of aceclofenac, manufacturer -Gedeon Richter.
The statistical processing of research results was done using IBM SPSS 20.0. The Wilcoxon Signed Ranks Test and Mann-Whitney Test were used. ANCOVA (Analysis of Covariance) was used for multi-factor analysis and the Post-hoc Sidac was used to detrermine significant differences between groups. A p < 0.05 was considered as statistically significant.
RESULTS
The average age of patients (SD) was 53.33 (12.42) years. Before the study alcohol was regularly consumed by 63 patients (59.4%), and 54 patients were smokers (50.9%). Average disease duration was: median = 36; IQR = 78 months.
Patients in the pancreatin monotherapy group experienced statistically significant improvement regarding abdominal pain, appetite loss, WBC count, blood a-amylase, ASAT, ALAT and urea (see Table 5 ).
Patients in the combined pancreatin and PPI therapy group had significant improvement of abdominal pain, bowel movements, steatorrhea, WBC count, ESR, blood a-amylase, ALAT, ASAT and CPI (see Table 6 ).
Patients in the combined pancreatin, PPI and NSAID therapy group (PNP therapy) after treatment experienced significant improvements in BMI, abdominal pain, bowel movements, appetite, steatorrhea, blood a-amylase, WBC count, ESR, CPI and VPI (see Table 7 ).
CP therapy safety indicators, such as RBC count and haemoglobin, remained constant after treatment in all groups of For explanations see Table 5. patients; moreover, they were similar after treatment between groups. In the pancreatin monotherapy group and pancreatin and PPI combined therapy group, ASAT and ALAT levels decreased significantly after treatment, while in the pancreatin, PPI and NSAID combined therapy group they remained unchanged. Urea showed a drop only in the pancreatin monotherapy group; in the other groups urea did not significantly differ. A significant CPI reduction was observed in the pancreatin and PPI combined therapy group and pancreatin, PPI and NSAID combined therapy group (P < 0.001); VPI differed significantly only in the pancreatin, PPI and NSAID combined therapy group patients (P < 0.001). Significant differences between groups are summarised in Table 8 .
According to EORTC QLQ-C30, CP symptom severity declined in all groups (P < 0.05) after treatment. EORTC QLQ-C30 global health significantly improved in all study groups (P < 0.05), functioning (sum of functioning scale points) improved in the pancreatin and PPI combined therapy group and pancreatin, PPI and NSAID combined therapy group (P < 0.05). Sum of points for QLQ-PAN26 significantly increased in all study groups (P < 0.05).
Analysis of covariance (ANCOVA) indicated significant differences between groups after the treatment for BMI, abdominal pain, bowel movements, appetite loss, clinical pancreatic index (see Table 8 ), as well as sum of points for EORTC QLQ-C30 CP symptom severity, global health, functioning and QLQ-PAN26.
DISCUSSION
A prospective, randomised, controlled study of combined medical therapy of CP was carried out to determine the most effective treatment of patients with CP: by using either pancreatin alone or in combination with PPI or PPI and non-steroidal anti-inflammatory drug (NSAID).
Abdominal pain is one of the hallmark symptoms of CP, and in this study 97.2% patients noted its presence. To evaluate abdominal pain, both the opinion of the patient and the judgment of the treating physician were taken into consideration. Patient's opinion was evaluated according to entries from the diary, by using both the modified visual analogue scale and several questions from the quality of life questionnaires (questions Nr. 9 and 19 of the EORTC QLQ-C30 and questions Nr. 33 and 34 of the QLQ-PAN26).
Several studies about the analgesic effect of the pancreatins have shown conflicting results, but meta-analysis concluded that they are not effective for relieving abdominal pain in case of CP (Brown et al., 1997) . This could be explained by the very heterogeneous patient population in terms of both the etiology and the severity of the disease, as well as the pharmaceutical formulation of pancreatin used and the duration of the treatment. Therefore, in our opinion, the results of this meta-analysis remain questionable. It is important to remember the CP is not a homogenous disease. There are at least six types depending on the etiology, and the clinical course is highly variable, ranging from intermittent to persistent abdominal pain or development of pancreas burnout syndrome. The causes of abdominal pain also can be quite different -large duct disease is more frequently associated with chronic pain that resists treatment, in comparison to small duct disease, which often has a much better response. This study included 84.5% patients with small duct disease, which might explain the increased effectiveness of pancreatin.
Four studies that evaluated the use of enteric coated pancreatin showed an analgesic effect that was close to that of the placebo (Halgreen et al., 1986; Larvin et al., 1991; Mössner et al., 1992; Malesci et al., 1995) . That might be explained by the fact that the enzymes in these studies were released outside duodenum, and therefore they were not able to suppress the secretion of cholecystokinin. Interestingly, in all studies showing lack of effectiveness of pancreatin for treatment of abdominal pain in CP, there was a paradoxically high placebo effect -up to 40% (Halgreen et al., 1986; Mössner et al., 1989; Mössner et al., 1992; Malesci et al., 1995) , despite the fact that frequently such pain is treatment resistant. Several explanations have been given for the exceptionally high placebo effect. Firstly, most of the studies had a crossover design, which lacked a wash-out period, thereby artificially increasing the placebo effect (Halgreen et al., 1986; Mössner et al., 1992; Malesci et al., 1995) . Secondly, three of four studies that showed a lack of effectiveness of the pancreatin for the treatment of abdominal pain in CP had a short treatment durationfrom one to two weeks, which may be insufficient to For explanations see Table 5 .
achieve the desired effect. Thirdly, the above cited studies used high doses of pancreatin, which exceeded the recommended dosage for the treatment of steatorrhea. The patients in one study received 10 000 IU of proteases/day (Mössner et al., 1992) whereas the patients in our study received only 3750 IU/day. It has been shown that high doses of proteases can stimulate rather than decrease exocrine secretion of pancreas, thereby promoting secretion of cholecystokinin and in such a way increasing pain (Mössner et al., 1989; Mössner et al., 1991) . However, a recent meta-analysis study of abdominal pain due to CP concluded that the placebo effect on abdominal pain is lower and can be observed in 20% of cases (Capurso et al., 2012) . In previous studies this possibly hindered study of the effect of enteric coated pancreatin in decreasing abdominal pain. In our study a moderate 34% (p < 0.05) analgesic effect of pancreatin was observed.
The existing guidelines for treatment of CP recommend the use of PPIs to increase the effect of pancreatin only in cases of steatorrhea (Warshaw et al., 1998; Frulloni et al., 2010; de-Madaria et al., 2013) . However, when pathogenesis of CP is taken into consideration, PPIs can be useful not only in decreasing secretion of gastric acid but also in decreasing exocrine secretion of pancreas, as PPIs can block the ATP-ases of pancreas duct cells (Novak et al., 2011) . As a result, a decline of bicarbonate and water production in pancreas ducts can be expected with subsequent reduction of abdominal pain. In our study the combination of PPI and pancreatin was more effective in decreasing abdominal pain, impaired bowel movements and steatorrhea and for improving quality of life, when compared to pancreatin monotherapy. Thereby our study shows that, in addition to previously published guidelines, PPIs can have a wider application for treatment of CP.
Most of the national guidelines include NSAIDs as a treatment for CP (Warshaw et al., 1998; Frulloni et al., 2010; de-Madaria et al., 2013) . One study showed that sulindac was not only an effective analgesic for CP, but also decreased both the fibrosis of the pancreas and the parenchymal infiltration with immune cells (Bai et al., 2012) . As any other drug, NSAIDs have risk of adverse effects. The most serious among those are gastrointestinal and cardiovascular events, but the frequency of such adverse effects in case of CP has not been studied. The common concerns about conventional NSAIDs partially stem from the frequent use of these medications without any kind of gastric protection, and from the fact that the prescription guidelines are frequently ignored. Studies have shown that the selective COX-2 inhibitors are much less toxic and that by adding a PPI the risk of gastrointestinal complications is greatly reduced. A combination of selective NSAID and a PPI is also economically advantageous, as the PPIs are relatively cheap but their beneficial impact is great. As only 1/3 of patients who are using NSAIDs are being prescribed an appropriate gastric protection and only 44% of these patients are adhering to such recommendations (Gigante and Tagarro, 2012; Jonasson et al., 2013) , fixed dose combinations of a NSAID and a PPI are becoming increasingly popular. Cardiovascular risks of NSAIDs have been evaluated in meta-analysis of thirty one randomised controlled trials dedicated to seven NSAIDs: naproxen, ibuprofen, diclofenac, celecoxib, etoricoxib, rofecoxib and lumiracoxib (Trelle et al., 2011) . The majority of the mentioned studies recommended an over three-month long therapy for patients with rheumatoid arthritis and osteoarthritis. These patients may have higher cardiovascular risk due to limited physical activity. In case of many illnesses the benefit of applying NSAIDs exceeds the risks of adverse effects, under condition that NSAID is used in small doses for a short period of time. In the given study NSAID was represented by aceclofenac, which is not a selective COX-2 inhibitor, however aceclofenac inhibits COX-2 more potently than COX-1. Therefore, it is much safer than many other NSAIDs in terms of gastrointestinal adverse effects. Moreover, the aceclofenac dosage was set according to manufacturer recommendations (30 days), which can be considered a short-term therapy. Strict compliance with NSAID therapy contraindications such as gastric or duodenum ulcer, gastrointestinal bleeding in anamnesis, severe liver and kidney diseases, acute cerebral or myocardial infarction and significant heart failure, which served as exclusion criteria in the given study, allowed to avoid the possible side effects of aceclofenac. In the given study, in order to assess the safety of aceclofenac, before and after treatment, several indicators were used: hemoglobin level, RBC count, fecal occult blood, ALAT, ASAT and urea. The analysis of study results showed that after therapy the mentioned indicants did not worsen in patients who received aceclofenac as a part of pancreatin, PPI and NSAID combined therapy. There were no gastrointestial and cardiovascular events during the study in the pancreatin, PPI and NSAID combined therapy group but one patient from the pancreatin monotherapy group had nonfatal stoke.
The results of this study showed that for reduction of abdominal pain and impaired bowel movements in patients with CP, PNP therapy is more effective than treatment with pancreatin alone or than treatment with a combination of pancreatin and a PPI. In addition, such treatment also increases the BMI and improves the clinical course of the disease and the quality of life. A one-month long course of PNP therapy in patients with CP was safe and did not cause any significant side effects. Such treatment of CP is rational, as it is based on pathogenesis, effectivity, safety and cost.
